The standard chemotherapy for ovarian cancer includes the combination of paclitaxel and a platinum compound. Comparing
carboplatin /paclitaxel with cisplatin/paclitaxel, it has been found that substitution of the analog carboplatin for cisplatin in this
combination may improve the toxicity profile.
1) To grade toxicity (according to WHO toxicity scale) and to compare the toxicity profile of cisplatin/paclitaxel versus carboplatin/
paclitaxel in advanced epithelial ovarian carcinoma.
2) To compare the performance status of patients receiving these regimens.
3) To assess the clinical response rate based on CA 125 criteria.
Methodology: 80 patients diagnosed with advanced epithelial ovarian cancer (stage III and stage IV), were recruited for the
study and were divided into two groups of 40 each. One group received cisplatin-paclitaxel and the other received carboplatinpaclitaxel.
All toxicities were graded according to WHO toxicity grading criteria. Response was assessed by CA 125 criteria, and
patients categorized as responders or non responders based on whether raised serum CA 125 (pretreatment) values decreased
by 50% during therapy.
Results: Hematological toxicity namely anemia, leucopenia and thrombocytopenia were significantly more in patients treated
with carboplatin. Nephrotoxicity, ototoxicity, neurotoxicity, nausea, vomiting and diarrhea were significantly more with cisplatin(p
Ovarian cancer, Hematological toxicity, Leucopenia, Thrombocytopenia